Exor NV
XMUN:EYX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Exor NV
XMUN:EYX
|
NL |
Exor NV
Exor N.V. is a holding company, not a factory or a retailer. It owns stakes in businesses across cars, trucks, farm equipment, luxury goods, media, and healthcare, and it often takes a long-term role in those companies rather than trading in and out of them. Its best-known holdings have included major automotive and industrial companies, along with a few private businesses. Exor does not sell products directly to consumers. It makes money mainly from the companies it owns: dividends, gains when it sells investments, and sometimes income from businesses it fully owns or controls. For beginner investors, the key idea is that Exor is a portfolio owner that turns its capital into ownership stakes in operating businesses. What makes Exor different is that it acts as an active owner, not a passive fund. It often supports management, helps shape strategy, and holds positions for many years, especially in businesses where it sees room to build value over time. That gives it a role as a patient capital provider in industries that need strong long-term ownership.
Exor N.V. is a holding company, not a factory or a retailer. It owns stakes in businesses across cars, trucks, farm equipment, luxury goods, media, and healthcare, and it often takes a long-term role in those companies rather than trading in and out of them. Its best-known holdings have included major automotive and industrial companies, along with a few private businesses.
Exor does not sell products directly to consumers. It makes money mainly from the companies it owns: dividends, gains when it sells investments, and sometimes income from businesses it fully owns or controls. For beginner investors, the key idea is that Exor is a portfolio owner that turns its capital into ownership stakes in operating businesses.
What makes Exor different is that it acts as an active owner, not a passive fund. It often supports management, helps shape strategy, and holds positions for many years, especially in businesses where it sees room to build value over time. That gives it a role as a patient capital provider in industries that need strong long-term ownership.
Portfolio: Exor accelerated its portfolio simplification, completing sales of GEDI, Lifenet and NUO, and signing an agreement to sell Welltec, expected to close in the first half of 2027.
Cash: Exor expects about EUR 4 billion of deployable cash, including proceeds from disposals and other inflows; after a EUR 500 million buyback, it expects about EUR 3.5 billion to remain.
Buyback: The company began a EUR 500 million on-market share buyback to run over the next six months, citing a 56% discount to NAV and the opportunity to invest in its own portfolio at a substantial discount.
NAV: NAV declined by EUR 1.2 billion, mainly reflecting listed holdings, with Stellantis the largest negative contributor; the discount to NAV widened and weighed on shareholder returns.
Investing: Exor says it is not rushing to deploy capital and is seeking large listed businesses where it can take a 15%–20% stake, generally investing at least EUR 2 billion.
Outlook: Management remains confident in Stellantis' announced recovery plan but said it had no knowledge of plans for a cash raise. It described further investment opportunities as a matter of patience and disciplined pricing.